Diseases of the endocrine system in children in Ukraine and the provision of specialized care to pediatric patients in 2020

2021 ◽  
pp. 4-14
Author(s):  
N. B. Zelinska ◽  
N. G. Rudenko ◽  
E. V. Globa ◽  
O. V. Rudenko ◽  
К. Grishchenko ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Growth Hormone ◽  
Short Stature ◽  
Turner Syndrome ◽  
Sex Differentiation ◽  
Endocrine System ◽  
The State ◽  
Pediatric Endocrinology ◽  
Endocrine Diseases ◽  
Specialized Care

The articles provide information and analysis of statistical indicators on the state of endocrinological care for children in 2020 in general in Ukraine and in some regions, their dynamics for 2014—2020. Providing data on staffing of the pediatric endocrinology service; the state of inpatient care for children with endocrine diseases; disability due to endocrine pathology, which has been carried out in recent years, is constantly growing, in particular diabetes, hypothyroidism and others; diseases and prevalence of malignant diseases of the endocrine glands in children. It is also possible to provide data from the register of children with active endocrine diseases, namely, diabetes mellitus, including its various forms, pathological short stature, the disorders of sex differentiation (DSD). The problematic issues of specialized care for children with diseases of the endocrine system are highlighted.It is estimated that according to the register of children with diabetes mellitus (DM) in 2020, 10,743 patients under the age of 18 were registered (14.26 per 10,000 children), including 10,598 children receiving insulin therapy (with DM Type 1, other types of diabetes requiring insulin treatment) (14.07), 51 — with DM type 2, 66 children with neonatal diabetes, of which 36 diagnoses are genetically confirmed, and MODY is genetically confirmed in 48 children. The prevalence of diabetes among children aged 0—18 years in 2020 increased compared to 2014 by 34.9 %.For patients with DSD conduct a detailed cytognetic examination in the leading genetic laboratories. Responding to the database of such children, to which 654 patients were includ, in particular with chromosomal DSD — 347 children (53.1 %, 303 patients with Turner syndrome); of 46, XY DSD — 102 patients (15.6 %); of 46, XX — 205 patients (31.3 %), as well as 185 children with DSD due to congenital adrenal hyperplasia.It is reported that in 2020, 1,630 children with short stature under the age of 18 who need treatment with growth hormone were registered in Ukraine, including 1,223 children with pituitary and pituitary-cerebral dwarfism, 255 children with Turner syndrome, 65 — with Russell—Silver syndrome, 43 — with Prader—Willi syndrome, 21 children with short stature, born small for their gestational age (SGA), as well as 22 children with dwarfism due to chronic renal failure. The number of such volumes increases by an average of 10 %. These children receive treatment with growth hormone drugs at the expense of the state budget.

scholarly journals Turner Syndrome, Uncommonly Diagnosed Cause of Short Stature: Case Report and Review of Literature

2013 ◽  
Vol 33 (1) ◽  
pp. 74-76
Author(s):  
S Basnet ◽  
A Eleena ◽  
AK Sharma
Keyword(s):  
Growth Hormone ◽  
Short Stature ◽  
Turner Syndrome ◽  
Age Estimation ◽  
Bone Age ◽  
Review Of Literature ◽  
X Ray ◽  
Dysmorphic Features ◽  
The Past ◽  
Hormone Analysis

Many children are frequently brought to the paediatric clinic for evaluation of short stature. Evaluation for these children does not go beyond x-ray for bone age estimation and growth hormone analysis. Most of them are considered having constitutional or genetic cause for their short stature. However, shuttle dysmorphic features could be missed in many of them. Hence, many children might be having chromosomal anomaly as an underlying cause. We report a case of 40 months who had been evaluated several times in the past for pneumonia, otitis media and short stature is finally diagnosed to have Turner syndrome. DOI: http://dx.doi.org/10.3126/jnps.v33i1.8174 J Nepal Paediatr Soc. 2013;33(1):74-76

Diabetes mellitus in anaesthesia

2012 ◽  
Vol 12 (2) ◽  
pp. 60-64 ◽  
Author(s):  
Jadelis Giquel ◽  
Yiliam F Rodriguez-Blanco ◽  
Christina Matadial ◽  
Keith Candiotti
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Immune Deficiency ◽  
Autonomic Neuropathy ◽  
Endocrine System ◽  
Morbidity And Mortality ◽  
Cardiovascular Autonomic Neuropathy ◽  
Operative Morbidity ◽  
Endocrine Diseases ◽  
Collagen Tissue

Anaesthesiologists frequently encounter patients with diseases of the endocrine system, in particular diabetes mellitus. The major risk factors for people with diabetes undergoing surgery are the associated end-organ diseases: cardiovascular autonomic neuropathy, joint collagen tissue, and immune deficiency. Due to the fact that endocrine diseases can be associated with significant peri-operative morbidity and mortality, it is critical that anaesthesiologists understand these disorders and when indicated request the appropriate investigations.

Correlation of Urinary Albumin andβ-2-Microglobulin and Growth Hormone Excretion in Patients with Diabetes Mellitus and Short Stature*

1990 ◽  
Vol 71 (3) ◽  
pp. 611-617 ◽  
Author(s):  
FUPING PAN ◽  
JANET L. STEVENSON ◽  
DAVID L. DONALDSON ◽  
JANET LEVY ◽  
THOMAS WIEGMANN ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Growth Hormone ◽  
Short Stature ◽  
Urinary Albumin ◽  
Patients With Diabetes ◽  
Hormone Excretion

scholarly journals Disease Profile and Socio-economic Status of Patients Attending at Endocrine Outpatient Department of a Tertiary Level Hospital

1970 ◽  
Vol 11 (1) ◽  
pp. 24-27
Author(s):  
Md Abdul Mannan ◽  
Kazi Jahangir Hossain ◽  
Md Mustafa Kamal
Keyword(s):  
Diabetes Mellitus ◽  
Socioeconomic Status ◽  
Economic Status ◽  
Endocrine System ◽  
Outpatient Department ◽  
Endocrine Disease ◽  
Endocrine Diseases ◽  
System Disease ◽  
Disease Pattern ◽  
Male Patients

The aim of this study was to find out the pattern of endocrine diseases and socioeconomic status of the patients attending at outpatient department of endocrinology of Sir Salimullah Medical College Mitford Hospital, Dhaka. A total of 498 endocrine patients were selected on the basis of defined criteria from September 2007 to August 2008. Of the 498 patients, 292 were female and 206 male. Majority of female patients were housewives (86.3%) while most of the male patients were businessmen (86.4%). Majority of them (59.4%) were in the age range of 41-75 years and 92.0% were married. About 7% were found obese, comparatively more in male patients. In endocrine disease pattern, 36.9% had diabetes mellitus, 18% hypothyroidism and 6.0% goiter. Impaired glucose tolerance (IGT), hyperthyroidism, hirsutism, gynaecomastia, infertility, gestational diabetes mellitus (GDM), hyperprolactinemia and short stature were found in 2.0%, 1.6%, 1.6%, 1.2%, 0.8%, 0.8%, 0.4% and 0.4% respectively. About 30.0% of the endocrine patients were found to be associated with other non-endocrine diseases or obesity. Appropriate medical treatment facilities in combination with motivational enhancement therapies are needed to ensure proper medical management of these patients. Keywords: Endocrine disease, endocrine system disease, socioeconomic status. DOI:10.3329/jom.v11i1.4264 J Medicine 2010: 11: 24-27

scholarly journals Delayed Bone Age Might Accelerate the Response to Human Growth Hormone Treatment in Small for Gestational Age Children with Short Stature

2019 ◽  
Vol 2019 ◽  
pp. 1-6
Author(s):  
Jung-Eun Moon ◽  
Cheol Woo Ko
Keyword(s):  
Growth Hormone ◽  
Short Stature ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Human Growth ◽  
Bone Age ◽  
Pediatric Endocrinology ◽  
Gh Therapy ◽  
Gh Treatment ◽  
The Impact

Purpose. Growth hormone (GH) treatment is recommended to improve growth and psychosocial problems in short stature children born small for gestational age (SGA). Although GH therapy in these patients has been extensively studied, the impact of therapy according to delays in bone age (BA) is not known well. Objective. To investigate the effects of GH therapy in SGA patients with short stature according to BA delay. Methods. We retrospectively analyzed changes in height SD score (SDS) and BA/chronological age (CA) after 6 and 12 months of GH therapy in patients grouped according to BA delay. We studied 27 SGA children with short stature in the pediatric endocrinology clinic of Kyungpook National University Children’s Hospital. Results. Of the 27 patients, 9 had <2 years of BA delay, while 18 had >2 years of delay. There were no significant differences between the two groups in terms of gestational age and weight at birth, height SDS, IGF-1 SDS, and growth hormone dosage at the beginning of therapy. However, height SDS increased significantly in the group with >2 years of BA delay after 6 months of GH therapy (−2.50 ± 0.61 vs −1.87 ± 0.82; p=0.037) and 12 months (−2.27 ± 0.70 vs −1.63 ± 0.65; p=0.002). When height SDS was compared between with and without GHD, there were no significant differences. Conclusions. Delayed BA (>2 years) may impact the response to GH treatment in SGA children with short stature.

scholarly journals SAT-105 The Natural History of Pituitary Cysts in Patients with Growth Hormone Deficiency and Idiopathic Short Stature

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Zeyad El-Naghy ◽  
Nicholas Andrew Krasnow ◽  
James Haigney ◽  
Tara Patale ◽  
Liam McGuirk ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Short Stature ◽  
Idiopathic Short Stature ◽  
Hormone Deficiency ◽  
Pediatric Endocrinology ◽  
Post Contrast ◽  
Pituitary Cyst ◽  
Pituitary Cysts ◽  
Over Time

Abstract Background: The sequential follow-up of simple fluid-filled pituitary cysts (PC) has not been fully elucidated. In this study, we further report our follow up of PCs in a cohort of pediatric patients (PTs). Objective: To further analyze the sequential cyst volume (CV) change in short children. Patients and Methods: A pediatric endocrinology and neuroradiology center was queried for the presence of PCs. PTs who underwent multiple high resolution post-contrast MRIs (1mm slices) were subjects of this study. PTs with additional MRI abnormalities were excluded. Pituitary volumes (PV) and CVs were measured using the ellipsoid formula (LxWxH/2). The percentage of the gland occupied by the cyst (POGO) was measured and calculated. A cyst with a POGO ≤15% was defined as a small pituitary cyst (SPC), and a POGO &gt;15% was defined as a large pituitary cyst (LPC). 34 PTs met inclusion criteria, all of whom were diagnosed with short stature (23 growth hormone deficient (GHD) PTs and 11 idiopathic short stature (ISS) PTs). All PTs were receiving GH during data collection. Results: The mean (MN) and median (MD) ages for these subjects were 10.7 yrs ±3.5 and 11.1 yrs, respectively (RSP). Of the 34 PTs, 24 PTs’ (71%) initial MRI demonstrated a SPC and 10 PTs’ (29%) initial MRI demonstrated a LPC. The MN and MD times between first and second MRIs were 1.23 yrs and 0.83 yrs RSP, with a range (RG) of 0.14 to 4.08 yrs. The MN and MD ΔCV for all PTs was 23.33% ±179.17% and -25.94% RSP, with a RG of -100.00% to 763.94%. The MN and MD ΔPOGO by the cyst for all PTs was 48.59% ±313.26% and -36.84% RSP, with a RG of -100.00% to 1734.79%. The MN and MD ΔCV for PTs with a SPC was 10.68% ±2.65% and 11.09% RSP, with a RG of -100.00% to 763.94%. The MN and MD ΔPOGO by the cyst for PTs with a SPC was 78.33% ±369.96% and -31.34% RSP, with a RG of -100.00% to 1734.79%. The MN and MD ΔCV for PTs with a LPC was -24.60% ±51.89% and -26.57% RSP, with a RG of -88.57% to 91.38%. The MN and MD ΔPOGO by the cyst for PTs with a LPC was -22.79% ±44.90% and -40.46% RSP, with a RG of -80.95% to 47.11%. Statistical analysis showed no significant %ΔCV or %ΔPOGO when comparing male vs. female, SPC vs. LPC, GHD vs. ISS, or pre-pubertal vs. pubertal PTs. Analysis of ΔPOGO of the 24 SPC PTs demonstrated that 4 (17%) of them developed into LPCs. Analysis of the 10 LPC PTs showed that 6 (60%) of them shrunk into SPCs, one of which re-enlarged into a LPC, and another of which fluctuated between LPC and SPC over a period of 7.34 yrs and 9 sequential MRIs. None of the PTs experienced significant sequelae related to their PCs. Conclusion: CV can change greatly over time, however few sequelae should be expected. LPCs tend to demonstrate major changes in size and should be tracked for CV change. A minority of SPCs will develop into LPCs. Prediction of change in CV over time requires more sequential data. Change in CV did not appear to be influenced by GH therapy.

Sign in / Sign up

Export Citation Format

Share Document